Mark A. Espeland

Mark A. Espeland

Auto-generated profile, based on publicly available information

Mark A. Espeland

Department of Internal Medicine, Wake Forest University School of Medicine , Winston-Salem, North Carolina

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2004 in JAMA
Verified
Journal Article
Open access
PDF file
MEMark A. Espeland
Mark A. Espeland
SRStephen R. Rapp
Stephen R. Rapp
SSSally A. Shumaker
Sally A. Shumaker
RBRobert Brunner
Robert Brunner
JMJoAnn E. Manson
JoAnn E. Manson
JHJennifer Hays
Jennifer Hays
Age-associated memory impairment affects an estimated one fifth to one third of older individuals and has important individual, family, and societal costs.1,2 In older postmenopausal women, the potential impact of declining levels of sex hormones on cognitive functioning has received particular attention because of estrogen's presumptive beneficial effects on neurotransmitters,3 neuroconnectivity,4,5 and neuroprotection.6 Observational studies have suggested that long-term hormone therapy may attenuate cognitive aging in postmenopausal women, although randomized clinical trial results are inconsistent.7-12

25 August 2015 in JAMA
Verified
Journal Article
Open access
PDF file
KSKaycee M. Sink
Kaycee M. Sink
MEMark A. Espeland
Mark A. Espeland
CSCynthia Castro Sweet
Cynthia Castro Sweet
TCTimothy Church
Timothy Church
RCRon Cohen
Ron Cohen
FIfor the LIFE Study Investigators
for the LIFE Study Investigators
Epidemiological evidence suggests that physical activity is associated with lower rates of cognitive decline. Exercise is associated with improved cerebral blood flow and neuronal connectivity,1 maintenance or improvement in brain volume,2,3 and favorable changes in brain-derived neurotrophic factor and neurogenesis.4,5 In transgenic Alzheimer mouse models, exercise reduces β-amyloid deposition.6

12 August 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
MEMark A. Espeland
Mark A. Espeland
SSSally A. Shumaker
Sally A. Shumaker
ILIris Leng
Iris Leng
JMJoAnn E. Manson
JoAnn E. Manson
CBCandice M. Brown
Candice M. Brown
SRSusan M. Resnick
Susan M. Resnick
The Women’s Health Initiative Memory Study (WHIMS) demonstrated that postmenopausal hormone therapy with conjugated equine estrogens (CEEs), when prescribed to women 65 years and older, produced deficits in global and domain-specific cognitive functioning.1-3 On average, these were small; however, deficits persisted for years after cessation of hormone therapy.3 They occurred in conjunction with decreases in brain volume linked to increased incidence of cognitive impairment.4,5

10 March 2005 in Current Controlled Trials in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MEMark A Espeland
Mark A Espeland
DODaniel H O'LEary
Daniel H O'LEary
JTJames Gregory Terry
James Gregory Terry
TMTimothy Morgan
Timothy Morgan
GEGreg Evans
Greg Evans
HMHarald Mudra
Harald Mudra
Background: Surrogate measures for cardiovascular disease events have the potential to increase greatly the efficiency of clinical trials. A leading candidate for such a surrogate is the progression of intima-media thickness (IMT) of the carotid artery; much experience has been gained with this endpoint in trials of HMG-CoA reductase inhibitors (statins). Methods and Results: We examine two separate systems of criteria that have been proposed to define surrogate endpoints, based on clinical and statistical arguments. We use published results and a formal meta-analysis to evaluate whether progression of carotid IMT meets these criteria for HMG-CoA reductase inhibitors (statins). IMT meets clinical-based criteria to serve as a surrogate endpoint for cardiovascular events in statin trials, based on relative efficiency, linkage to endpoints, and congruency of effects. Results from a meta-analysis and post-trial follow-up from a single published study suggest that IMT meets established statistical criteria by accounting for intervention effects in regression models. Conclusion: Carotid IMT progression meets accepted definitions of a surrogate for cardiovascular disease endpoints in statin trials. This does not, however, establish that it may serve universally as a surrogate marker in trials of other agents.

7 August 2014 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MEMark A. Espeland
Mark A. Espeland
HGHenry A. Glick
Henry A. Glick
ABAlain G Gerald Bertoni
Alain G Gerald Bertoni
FBFrederick L. Brancati
Frederick L. Brancati
GBGeorge A. Bray
George A. Bray
PZPing Zhang
Ping Zhang
OBJECTIVE To assess the relative impact of an intensive lifestyle intervention (ILI) on use and costs of health care within the Look AHEAD trial. RESEARCH DESIGN AND METHODS A total of 5,121 overweight or obese adults with type 2 diabetes were randomly assigned to an ILI that promoted weight loss or to a comparison condition of diabetes support and education (DSE). Use and costs of health-care services were recorded across an average of 10 years. RESULTS ILI led to reductions in annual hospitalizations (11%, P = 0.004), hospital days (15%, P = 0.01), and number of medications (6%, P < 0.001), resulting in cost savings for hospitalization (10%, P = 0.04) and medication (7%, P < 0.001). ILI produced a mean relative per-person 10-year cost savings of $5,280 (95% CI 3,385–7,175); however, these were not evident among individuals with a history of cardiovascular disease. CONCLUSIONS Compared with DSE over 10 years, ILI participants had fewer hospitalizations, fewer medications, and lower health-care costs.

15 May 2001 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MEMark A. Espeland
Mark A. Espeland
SKShiriki Kumanyika
Shiriki Kumanyika
AWAlan C. Wilson
Alan C. Wilson
DRDavid M. Reboussin
David M. Reboussin
LELinda Easter
Linda Easter
MMMary McFarlane
Mary McFarlane
Dietary recalls and urine assays provide different metrics for assessing sodium and potassium intakes. Means, variances, and correlations of data obtained from these two modes of measurement differ. Pooling of these data is not straightforward, and results from studies employing the different modes may not be comparable. To explore differences between these metrics, the authors used data from the Trial of Nonpharmacologic Intervention in the Elderly (TONE), which included repeated standardized 24-hour dietary recalls and 24-hour urine collections administered over 3 years of follow-up, to estimate sodium and potassium intakes. The authors examined data from 341 control participants assigned to usual care that were collected between August 1992 and December 1995. Dietary recalls yielded estimates of sodium intake that averaged 22% less than those from urine assays and estimates of potassium intake that averaged 16% greater than those from urine assays. Sodium intake estimates were less repeatable (r = 0.22 for diet; r = 0.30 for urine) than potassium intake estimates (r = 0.49 for diet; r = 0.50 for urine), making relations with outcomes more difficult to characterize. Overall, the performance of the two measurement modes was fairly similar across demographic subgroups. Errors in separate estimations of long term sodium and potassium intakes using short term data were strongly correlated, more strongly than the underlying long term intakes of these electrolytes. Because of the correlated measurement error, estimated regression coefficients for linear models including both electrolytes as predictors may be confounded such that the separate relations between these nutrients and outcomes such as blood pressure cannot be reliably estimated by common analytical strategies.